Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences:

• A fireside chat at the Evercore ISI 4th Annual HealthCONx Conference at 11:20 a.m. ET / 8:20 a.m. PT on November 30, 2021; and
• A fireside chat at the JMP Securities Hematology and Oncology Summit at 2:20 p.m. ET / 11:20 a.m. PT on December 7, 2021.

Audio webcasts of the Evercore and JMP events will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets of patients, including those who have HRAS- and/or PIK3CA-dependent HNSCC. The Company is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:Pete De SpainVice President, Investor Relations &Corporate Communications(858) 500-8803[email protected]

Investors:Robert H. UhlManaging DirectorWestwicke ICR(858) 356-5932[email protected]

Media:Jason SparkManaging DirectorCanale Communications(619) 849-6005[email protected]

You May Also Be Interested In

• Seegnal Reports Second Quarter 2026 Financial Results and Provides Business Update
• Alexandria Real Estate Equities, Inc. Declares Cash Dividend of $0.72 per Common Share for 3Q26
• Tris Pharma to Showcase ADHD Leadership and Commitment to Individualized Care at Fall 2026 Medical Conferences